{"entity":{"id":"pf-07248144","kind":"drug","name":"PF-07248144","aka":[],"tldr":"PF-07248144 is an experimental small-molecule drug from Pfizer in phase 3 trials for HR-positive / HER2-negative breast cancer, prostate cancer and non-small-cell lung cancer, with its target not yet stated publicly.","summary":"PF-07248144 is a small-molecule drug developed by Pfizer. The sponsor describes its target as KAT6 (lysine acetyltransferase, e.g. KAT6A), which OnCo does not yet have a target page for. The sponsor states: PF-07248144 is a KAT6 inhibitor being studied as a single agent and in combination with fulvestrant, letrozole plus palbociclib, PF-07220060 (a CDK4 inhibitor) plus fulvestrant, or vepdegestrant, in HR-positive/HER2-negative breast cancer and other solid tumours. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07062965 (A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment), in HR-positive / HER2-negative breast cancer, prostate cancer and non-small-cell lung cancer. The largest, NCT07062965, plans to enrol 400 participants with primary completion expected 2027-07-22. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of PF-07248144","url":"https://clinicaltrials.gov/search?intr=PF-07248144"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-hr-positive","prostate","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["pfizer"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07062965","nct04606446"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule","mechanism":"PF-07248144 is a KAT6 inhibitor being studied as a single agent and in combination with fulvestrant, letrozole plus palbociclib, PF-07220060 (a CDK4 inhibitor) plus fulvestrant, or vepdegestrant, in HR-positive/HER2-negative breast cancer and other solid tumours.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/pf-07248144/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"company":[{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/"}],"trial":[{"id":"nct07062965","kind":"trial","name":"A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment","route":"/trials/nct07062965/"},{"id":"nct04606446","kind":"trial","name":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","route":"/trials/nct04606446/"}]}}